Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 9/20 | 0.65 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.65 |
| ▸ | PIM1 | P11309 | 8/20 | 0.58 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614408 | 0.87 | FYN (0.51) | FYNMKNK1PIM1 | |
| SCHEMBL12614409 | 0.87 | FYN (0.51) | FYNMKNK1PIM1 | |
| SCHEMBL1051076 | 0.86 | MKNK1 (0.63) | FYNMKNK1PIM1MALT1KCNH2 | |
| SCHEMBL12350844 | 0.84 | PIM1 (0.58) | FYNMKNK1PIM1MALT1KCNH2 | |
| SCHEMBL12351207 | 0.84 | MKNK1 (0.48) | FYNMKNK1PIM1MALT1KCNH2 | |
| SCHEMBL12351084 | 0.84 | PIM1 (0.58) | FYNMKNK1PIM1MALT1KCNH2 | |
| SCHEMBL1054446 | 0.84 | PIM1 (0.60) | FYNMKNK1PIM1MALT1KCNH2 | |
| SCHEMBL2359110 | 0.84 | PIM1 (0.58) | FYNMKNK1PIM1MALT1KCNH2 | |
| SCHEMBL16009992 | 0.84 | PIM1 (0.60) | FYNMKNK1PIM1MALT1KCNH2 | |
| SCHEMBL2355377 | 0.83 | FYN (0.47) | FYNMKNK1PIM1MALT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | THE UAB RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2021216757-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021216757-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-2822559-B1 | IMIDAZO[1,2-B]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | LEXICON PHARMACEUTICALS INC (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-2822559-B1 | IMIDAZO[1,2-B]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | LEXICON PHARMACEUTICALS INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20170057964-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20160024093-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-8969565-B2 | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969565-B2 | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969565-B2 | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130245021-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-19 | — | — | US | disclosed |
| US-20130245021-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-19 | — | — | US | disclosed |
| US-20130245021-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-19 | — | — | US | disclosed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2063962-A2 | IRAK MODULATORS FOR TREATING AN INFLAMMATORY CONDITION, CELL PROLIFERATIVE DISORDER, IMMUNE DISORDER | Biogen Idec MA Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008030579-A2 | IRAK MODULATORS FOR TREATING AN INFLAMMATORY CONDITION, CELL PROLIFERATIVE DISORDER, IMMUNE DISORDER | BIOGEN IDEC MA INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | FYN 666/4885MKNK1 105/4885PIM1 147/4885 |
| US-20160024093-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | FYN 712/4885MKNK1 138/4885PIM1 756/4885 |
| US-20170057964-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | FYN 712/4885MKNK1 138/4885PIM1 756/4885 |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | HNRNPR, HNRNPAB, RBM3 | FYN 2657/4885MKNK1 1675/4885PIM1 1866/4885 |
| US-20130245021-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | FYN 712/4885MKNK1 138/4885PIM1 756/4885 |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | HNRNPR, HNRNPAB, RBM3 | FYN 2657/4885MKNK1 1675/4885PIM1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.